Core Viewpoint - Kanghui Pharmaceutical (603139.SH) reported a decline in revenue and an increase in net losses for the first half of 2025, indicating financial challenges for the company [1] Financial Performance - The company's operating revenue for the first half of 2025 was 248 million yuan, a year-on-year decrease of 6.83% [1] - The net loss attributable to shareholders of the listed company was 40.2036 million yuan, which represents a year-on-year increase of 362.01% [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 42.8271 million yuan, reflecting a year-on-year increase of 167.89% [1] - The basic loss per share was 0.4 yuan [1]

Core Points - The company, Shaanxi Kanghui Pharmaceutical Co., Ltd., has obtained a new drug production license valid until August 24, 2030, ensuring compliance and continuity in operations [1][2] - The new license was issued by the Shaanxi Provincial Drug Administration due to the expiration of the previous license, which is a routine regulatory process [1][2] Company Information - The new drug production license number is 陕 20160073, and the company is located in Xi'an, Shaanxi Province [1] - The legal representative and responsible person for quality is Wang Yanling, while the production manager is Guo Jiangang [1] Production Scope - The company is authorized to produce a variety of pharmaceutical forms including plasters, ointments, granules, hard capsules, tablets, tinctures, and more across multiple production sites in Xi'an [1]

Core Viewpoint - Kanghui Pharmaceutical announced the acquisition of a new drug production license from the Shaanxi Provincial Drug Administration, effective August 25, 2025 [2] Company Summary - Kanghui Pharmaceutical received a renewed drug production license, indicating compliance with regulatory standards and potential for increased production capacity [2]

Group 1 - The core point of the article is that Kanghui Pharmaceutical has provided guarantees totaling approximately 112 million yuan for its subsidiaries, which represents 13.35% of the company's latest audited net assets [1] - As of the announcement date, the market capitalization of Kanghui Pharmaceutical is 2.4 billion yuan [1] - The revenue composition for Kanghui Pharmaceutical in 2024 is as follows: 49.58% from pharmaceutical manufacturing, 47.35% from pharmaceutical distribution, and 3.07% from other businesses [1] Group 2 - The company has provided a guarantee balance of 2.8 million yuan for its wholly-owned subsidiary [1] - The A-share market has seen a continuous trading volume exceeding 2 trillion yuan for eight consecutive days, indicating a robust trading environment [1] - Major industry players are actively recruiting for 25 positions, highlighting a demand for talent in the sector [1]

关于为控股子公司提供担保的公告 证券代码：603139 证券简称：康惠制药 公告编号：2025-051 陕西康惠制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | | | 被担保人名称 本次担保金额 | 480 | 四川春盛药业集团股份有限公司 万元 | | | --- | --- | --- | --- | --- | --- | | 担 | 保 对 | | | | | | 象 | | 实际为其提供的担保余额 | 2,880 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 11,442.84 | | 对外担保总额占上市公司最近一期经审计净资产的比例（%） | 13.35 ...

证券代码：603139 证券简称：康惠制药 公告编号：2025-052 陕西康惠制药股份有限公司 关于换发药品生产许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、《药品生产许可证》的主要信息 企业名称：陕西康惠制药股份有限公司 许可证编号：陕 20160073 社会信用代码：916100006984144239 分类码：AhzCz 注册地址：陕西省咸阳市秦都区高新技术产业开发区彩虹二路 法定代表人：王延岭 企业负责人：王延岭 质量负责人：郝红梅 质量授权人：郝红梅 陕西康惠制药股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日取得 陕西省药品监督管理局换发的《药品生产许可证》（许可证编号：陕 20160073）， 换发后的《药品生产许可证》有效期至 2030 年 8 月 24 日，具体情况如下： 生产地址和生产范围： 陕西省咸阳市秦都区高新技术产业开发区胭脂路 36 号：膏药，软膏剂，茶 剂，颗粒剂，硬胶囊剂，片剂，酒剂，合剂，搽剂，酊剂，洗剂； 陕西省咸阳市秦都区高新开发区高新路:搽剂,酊剂 ...

Group 1 - The company held its 18th meeting of the 5th Board of Directors on August 19, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][5] - The board approved the proposal to cancel the supervisory board and amend the Articles of Association, transferring the supervisory board's powers to the audit committee of the board [3][39] - The proposal to amend the Articles of Association requires approval at the company's second extraordinary general meeting in 2025 [4] Group 2 - The board also approved the revision of 23 governance rules to enhance the company's governance structure, which will also be submitted for approval at the upcoming extraordinary general meeting [6][39] - A new management system for the departure of directors and senior management was established and disclosed [7] - The board nominated candidates for the 6th Board of Directors, including both non-independent and independent directors, all requiring approval at the extraordinary general meeting [9][15][39] Group 3 - The company announced the date and details for the second extraordinary general meeting, scheduled for September 4, 2025, at 14:30 [21][20] - Voting will be conducted through a combination of on-site and online methods, with specific timeframes for each [22][24] - The company will provide reminders to minority investors to ensure their participation in the voting process [27]

Core Viewpoint - The company is undergoing a board restructuring process, including the nomination of candidates for the sixth board of directors and the establishment of new governance policies to enhance operational standards and corporate governance [3][4][20]. Group 1: Board Restructuring - The fifth board of directors has completed its term, and the company plans to elect a new sixth board consisting of nine members, including three independent directors and one employee representative [3][5]. - The board candidates have been nominated and will be subject to approval at the upcoming extraordinary general meeting [4][5]. - The election will utilize a cumulative voting system, and the new board's term will commence upon approval by the shareholders [5]. Group 2: Governance Policy Updates - The company is revising several governance policies, including the management of resignations for directors and senior management, to align with legal requirements and improve governance structures [2]. - The revised policies will also be presented for approval at the extraordinary general meeting [2]. Group 3: Candidate Qualifications - All nominated candidates meet the legal and regulatory requirements for board membership, with no disqualifications or conflicts of interest reported [6][10][21]. - The independent director candidates have completed the necessary training and have been approved by the Shanghai Stock Exchange [6][16]. Group 4: Employee Representative Election - The employee representative director has been elected by the employee representative assembly and will join the newly elected board [20][21].

Group 1 - The company announced the convening of its 18th meeting of the 5th Board of Directors on August 19, 2025, to discuss the revision of certain governance systems [2] - For the year 2024, the company's revenue composition is as follows: pharmaceutical manufacturing accounts for 49.58%, pharmaceutical distribution accounts for 47.35%, and other businesses account for 3.07% [2]

（文章来源：证券日报） 证券日报网讯 8月19日晚间，康惠制药发布公告称，公司第五届董事会第十八次会议审议通过了《关于 提请召开2025年第二次临时股东大会的议案》等多项议案。 ...